Health Canada Approves Yorvipath for Chronic Hypoparathyroidism Treatment

Pendopharm, a division of Pharmascience Inc., has announced the approval of Yorvipath (palopegteriparatide injection) for chronic hypoparathyroidism treatment in adults. Developed by Ascendis Pharma A/S, the parathyroid hormone replacement therapy is already approved in the US, EU, and other global markets. The approval follows an exclusive distribution agreement signed with Ascendis Pharma in July 2024. Pendopharm will be responsible for the regulatory approval and commercialization of Yorvipath in Canada.